Abzena plc

Cambridge, UK, 3 July 2017- Further to the announcement by Abzena plc (AIM: ABZA, 'Abzena' or the 'Group')on 9 January 2017, since 9 January 2017 and 3 July 2017, the Group announces that a total of nil ordinary shares of £0.002 each in the share capital of the Group ('Ordinary Shares') have been issued since that date pursuant to the Group's 2013 Share Incentive Plan and admitted to trading in accordance with the block listing applied for on 7 July 2015 (the 'Block Listing').An update in accordance with Schedule 6 of the AIM Rules for Companies is set out below. The Group holds no shares in treasury and hence the total number of current voting rights is 213,603,903.

BLOCK LISTING SIX MONTHLY RETURN

Name of applicant:

Abzena plc

Name of scheme:

Abzena plc 2013 Share Incentive Plan

Period of return:

From:

9 January 2017

To:

3 July 2017

Balance of unallotted securities under scheme(s) from previous return:

757,476

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

nil

Less: Number of securitiesissued/allotted under scheme(s) during period (see LR3.5.7G):

nil

Equals: Balance under scheme(s) not yet issued/allotted at end of period

757,476

Number and class of securities originally admitted and the date of admission

1,779,000 ordinary shares of £0.002 each, admitted on 13 July 2015

Name of contact:

Julian Smith

Telephone number of contact:

+44 1223 903 498

Enquiries:

Abzena plc

John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer

+44 1223 903498

Numis (Nominated Adviser and Broker)

Clare Terlouw / James Black / Paul Gillam

+44 20 7260 1000

N+1 Singer (Joint Broker)

Aubrey Powell / Liz Yong

+44 20 7496 3000

Instinctif Partners

Melanie Toyne Sewell / Alex Shaw

+44 20 7457 2020

abzena@instinctif.com

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'Abzena inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'Abzena inside' products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

· Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;

· Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;

· Cell line development for the manufacture of recombinant proteins and antibodies;

· Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

· Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

· Proprietary site-specific conjugation technologies and novel payloads for ADC development; and

· GMP manufacturer of ADC linkers, payloads & combined linker-payloads.

For more information, please seewww.abzena.com

Abzena plc published this content on 03 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 03 July 2017 17:17:09 UTC.

Original documenthttp://otp.investis.com/clients/uk/abzena/rns/regulatory-story.aspx?cid=897&newsid=888513

Public permalinkhttp://www.publicnow.com/view/4E2F84301A6F34A8BCA52A2DDB24D1247A6191CD